secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001093557-25-000291
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DexCom appoints Jacob Leach as CEO effective Jan 1, 2026; sets compensation terms
--------------------------------------------------------------------------------

- Jacob S. Leach promoted to CEO from President/COO; effective Jan 1, 2026, succeeding Kevin Sayer on medical leave.
- Annual base salary $1,150,000; target bonus 150% of base salary.
- Granted RSUs valued at $7.5M vesting over 3 years; PSUs target $7.5M based on performance.
- Sayer expected to return from medical leave ~March 2026; Foletta remains interim chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000291/0001093557-25-000291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000291/dxcm-20251219.htm
  HTML page:      https://secwatch.observer/filing/0001093557-25-000291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer